{"id":"W4402460449","doi":"10.1038/s41408-024-01135-2","title":"Belantamab mafodotin, pomalidomide, and dexamethasone for triple class exposed/refractory relapsed multiple myeloma: a subgroup analysis of the ALGONQUIN trial","year":2024,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"ca_institutions":"Canadiana.org; Juravinski Cancer Centre; Ottawa Hospital; University Health Network; CancerCare Manitoba; Princess Margaret Cancer Centre; Vancouver General Hospital; University of British Columbia; Queen Elizabeth II Health Sciences Centre; McMaster University; London Health Sciences Centre; Dalhousie University","funders":"","keywords":"Pomalidomide; Dexamethasone; Subgroup analysis; Multiple myeloma; Internal medicine; Oncology; Medicine; Refractory (planetary science); Lenalidomide; Meta-analysis; Biology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002966156,0.0009418646,0.003009901,0.0004949355,0.0002090546,0.001049355,0.0004485229,0.0006038087,0.001358464],"category_scores_gemma":[0.002132655,0.0002602951,0.006239943,0.000564211,0.0002755908,0.0004148876,0.0003922341,0.0009861192,0.0001793155],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004883475,"about_ca_system_score_gemma":0.0006319282,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006283575,"about_ca_topic_score_gemma":0.002103328,"domain_scores_codex":[0.9983134,0.0009602549,0.0001890275,0.0002208577,0.0001459888,0.0001704986],"domain_scores_gemma":[0.9989263,0.0004245851,0.0002193815,0.0002070956,0.00008027378,0.0001423262],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7429994,0.001311325,0.08042813,0.002210299,0.09363677,0.0008610665,0.0003616449,0.00276111,0.01764817,0.0003889041,0.002579566,0.05481361],"study_design_scores_gemma":[0.3251638,0.09215705,0.3948379,0.0005571911,0.1546727,0.002299143,0.001245813,0.008776434,0.005849432,0.00316355,0.01101562,0.0002614266],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9903324,0.007231895,0.0003068367,0.0002169841,0.00009245871,0.0003091498,0.0007051293,0.00001731771,0.0007878002],"genre_scores_gemma":[0.9974802,0.0008179456,0.0002012845,0.0001931382,0.00009047027,0.0001898333,0.0007044458,0.00001038079,0.0003122148],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003009901,"threshold_uncertainty_score":0.01568669,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03603070339032477,"score_gpt":0.3259702992284997,"score_spread":0.289939595838175,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}